Pel-Ebstein fever with cyclical pancytopenia.

Por Chng, W J, Howard, M R
Publicado em 2001

p53 Abnormalities and Potential Therapeutic Targeting in Multiple Myeloma

Por Teoh, P. J., Chng, W. J.
Publicado em 2014

Genetic events in the pathogenesis of multiple myeloma

Por Chng, W. J., Glebov, O., Bergsagel, P.L., Kuehl, W. M.
Publicado em 2007

T-cell death following immune activation is mediated by mitochondria-localized SARM

Por Panneerselvam, P, Singh, L P, Selvarajan, V, Chng, W J, Ng, S B, Tan, N S, Ho, B, Chen, J, Ding, J L
Publicado em 2013

Effect of dasatinib against thyroid cancer cell lines in vitro and a xenograft model in vivo

Por Chan, D., Tyner, J.W., Chng, W.J., Bi, C., Okamoto, R., Said, J., Ngan, B.D., Braunstein, G.D., Koeffler, H.P.
Publicado em 2012

Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia

Por Hart, S, Goh, K C, Novotny-Diermayr, V, Tan, Y C, Madan, B, Amalini, C, Ong, L C, Kheng, B, Cheong, A, Zhou, J, Chng, W J, Wood, J M
Publicado em 2011

Thrombotic microangiopathy during carfilzomib use: case series in Singapore

Por Chen, Y, Ooi, M, Lim, S F, Lin, A, Lee, J, Nagarajan, C, Phipps, C, Lee, Y S, Grigoropoulos, N F, Lao, Z, Surendran, S, Teh, E M, Goh, Y T, Chng, W J, Gopalakrishnan, S K
Publicado no Blood Cancer J (2016)

RUNX3 is oncogenic in natural killer/T-cell lymphoma and is transcriptionally regulated by MYC

Por Selvarajan, V, Osato, M, Nah, G S S, Yan, J, Chung, T-H, Voon, D C-C, Ito, Y, Ham, M F, Salto-Tellez, M, Shimizu, N, Choo, S-N, Fan, S, Chng, W-J, Ng, S-B
Publicado no Leukemia (2017)

Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study

Por Moreau, P, Joshua, D, Chng, W-J, Palumbo, A, Goldschmidt, H, Hájek, R, Facon, T, Ludwig, H, Pour, L, Niesvizky, R, Oriol, A, Rosiñol, L, Suvorov, A, Gaidano, G, Pika, T, Weisel, K, Goranova-Marinova, V, Gillenwater, H H, Mohamed, N, Aggarwal, S, Feng, S, Dimopoulos, M A
Publicado no Leukemia (2017)

Carfilzomib–dexamethasone vs bortezomib–dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR

Por Chng, W-J, Goldschmidt, H, Dimopoulos, M A, Moreau, P, Joshua, D, Palumbo, A, Facon, T, Ludwig, H, Pour, L, Niesvizky, R, Oriol, A, Rosiñol, L, Suvorov, A, Gaidano, G, Pika, T, Weisel, K, Goranova-Marinova, V, Gillenwater, H H, Mohamed, N, Feng, S, Aggarwal, S, Hájek, R
Publicado no Leukemia (2017)

JAK-STAT and G-protein-coupled receptor signaling pathways are frequently altered in epitheliotropic intestinal T-cell lymphoma

Por Nairismägi, M-L, Tan, J, Lim, J Q, Nagarajan, S, Ng, C C Y, Rajasegaran, V, Huang, D, Lim, W K, Laurensia, Y, Wijaya, G C, Li, Z M, Cutcutache, I, Pang, W L, Thangaraju, S, Ha, J, Khoo, L P, Chin, S T, Dey, S, Poore, G, Tan, L H C, Koh, H K M, Sabai, K, Rao, H-L, Chuah, K L, Ho, Y-H, Ng, S-B, Chuang, S-S, Zhang, F, Liu, Y-H, Pongpruttipan, T, Ko, Y H, Cheah, P-L, Karim, N, Chng, W-J, Tang, T, Tao, M, Tay, K, Farid, M, Quek, R, Rozen, S G, Tan, P, Teh, B T, Lim, S T, Tan, S-Y, Ong, C K
Publicado no Leukemia (2016)

Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia

Por Madan, V, Shyamsunder, P, Han, L, Mayakonda, A, Nagata, Y, Sundaresan, J, Kanojia, D, Yoshida, K, Ganesan, S, Hattori, N, Fulton, N, Tan, K-T, Alpermann, T, Kuo, M-C, Rostami, S, Matthews, J, Sanada, M, Liu, L-Z, Shiraishi, Y, Miyano, S, Chendamarai, E, Hou, H-A, Malnassy, G, Ma, T, Garg, M, Ding, L-W, Sun, Q-Y, Chien, W, Ikezoe, T, Lill, M, Biondi, A, Larson, R A, Powell, B L, Lübbert, M, Chng, W J, Tien, H-F, Heuser, M, Ganser, A, Koren-Michowitz, M, Kornblau, S M, Kantarjian, H M, Nowak, D, Hofmann, W-K, Yang, H, Stock, W, Ghavamzadeh, A, Alimoghaddam, K, Haferlach, T, Ogawa, S, Shih, L-Y, Mathews, V, Koeffler, H P
Publicado no Leukemia (2016)